Connect measurement strategy and interpretation across PK/TK, immunogenicity, and biomarkers.
Keep association, predictive value, and clinical validation separate. Findings from different studies, matrices, and assays are not automatically comparable.
Sources, selection, and corrections →The first six companies in this field’s editorial order, not a separate selection or capability ranking. The full directory uses the same data and order.
Manage field companies & order →
Crystal Bio Solutions offers Biologics mass spectrometry, CMC analytics, PK, immunogenicity and biomarkers. Services should be matched to the intended study and assay requirements.
WuXi AppTec offers Large-molecule bioanalysis, PK, immunogenicity and biomarkers. Services should be matched to the intended study and assay requirements.
Pharmaron offers Biologics characterization, PK/TK, immunogenicity and biomarkers. This is the analytical service business of an integrated CRO/CDMO.
BioAgilytix offers Large-molecule PK, ADA, neutralizing antibodies, biomarkers and CMC analytics. Services should be matched to the intended study and assay requirements.
SGS offers Protein characterization, potency, GMP release, stability and bioanalysis. Services should be matched to the intended study and assay requirements.
Eurofins BioPharma Services offers Biologics characterization, GMP testing, bioanalysis and clinical biomarkers. Services should be matched to the intended study and assay requirements.
Original online dates are retained. Guides use accessible articles or abstracts and do not replace reading the paper.
This review surveys improvements in proteomics sample preparation, instrumentation, data acquisition, and analysis. It connects single-cell and spatial profiling with protein interactions, modifications, and biomarker discovery in body fluids. Clinical implementation is discussed as an opportunity with remaining challenges, rather than proof that every discovery assay is ready for diagnostic use.
Tiannan Guo; Judith A Steen; Matthias Mann
DOI: 10.1038/s41586-025-08584-0
Manually selected historical and recent original announcements, not presented as today’s news. Source dates, including historical dates, are retained.
Wave's quarterly update describes planning for a registrational WVE-006 RNA-editing study in AATD and ongoing WVE-007 siRNA Phase 2a work. The company also reports FDA support for its LC-MS assay in the planned WVE-006 program. Regulatory feedback and trial plans do not constitute marketing approval or comparative efficacy evidence.
Original announcement ↗BioAgilytix announced a new 360biolabs laboratory in Sydney's Macquarie Park district. The company describes support for time-sensitive clinical samples, PBMC isolation, flow cytometry, and sample storage. It says shared procedures and quality systems support assay transfer across its laboratory network. These are company-reported capabilities.
Original announcement ↗